WO1999067218A2 - Method of preparing 5- or 8-bromoisoquinoline derivatives - Google Patents

Method of preparing 5- or 8-bromoisoquinoline derivatives Download PDF

Info

Publication number
WO1999067218A2
WO1999067218A2 PCT/DK1999/000347 DK9900347W WO9967218A2 WO 1999067218 A2 WO1999067218 A2 WO 1999067218A2 DK 9900347 W DK9900347 W DK 9900347W WO 9967218 A2 WO9967218 A2 WO 9967218A2
Authority
WO
WIPO (PCT)
Prior art keywords
process according
bromoisoquinoline
catalyst
bromoisoisoquinoline
hxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK1999/000347
Other languages
English (en)
French (fr)
Other versions
WO1999067218A3 (en
Inventor
Alex Haahr Gouliaev
William Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Priority to AT99927733T priority Critical patent/ATE250584T1/de
Priority to DK99927733T priority patent/DK1089976T3/da
Priority to JP2000555872A priority patent/JP2002518480A/ja
Priority to EP99927733A priority patent/EP1089976B1/en
Priority to DE69911603T priority patent/DE69911603T2/de
Priority to AU44987/99A priority patent/AU4498799A/en
Publication of WO1999067218A2 publication Critical patent/WO1999067218A2/en
Publication of WO1999067218A3 publication Critical patent/WO1999067218A3/en
Priority to US09/685,025 priority patent/US6500954B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines

Definitions

  • the present invention is directed to a method of preparing bromoisoquinoline derivatives, in particular 5- or 8-bromoisoquinoline derivatives.
  • Bromoisoquinoline derivatives, and in particular 5-bromoisoquinoline and 5-bromo-8-nitroisoquinoline derivatives, are key intermediates in the synthesis of pharmaceutical compounds.
  • Bromoisoquinoline derivatives and in particular 5-bromoisoquinoline and 5-bromo-8- nitroisoquinoline derivatives, are key intermediates in the synthesis of pharmaceutical compounds.
  • the direct bromination procedure tends to give mixtures of brominated products and in unsatisfactory yield, and none of the methods described are well suited for large scale work.
  • the indirect method is not very suitable for large scale work especially due to the diazotation step.
  • the method of the invention is particularly well suited for large scale work operation and for accomplishing "one- pot” synthesis.
  • the present invention provides a method of preparing bromoisoquinoline and its derivatives. More particularly, the invention provides a high yielding method for the synthesis of 5- or 8-bromoisoquinoline and its derivatives, in particular 5-bromo-8-nitroisoquinoline. Accordingly, in its most general aspect, the invention provides a process for the preparation of 5- or 8-bromoisoisoquinoline, or a derivative thereof, which process comprises the step of reacting isoquinoline, or a derivative thereof, with a brominating agent in the presence of a catalyst.
  • the brominating Agent used according to the present invention may be any suitable brominating agent. However, in a preferred embodiment, a suitable brominating agent is an agent of the general formula Z-Br, wherein Z represents a suitable leaving group.
  • the leaving group may be a secondary amino group of the general formula R 2 N-Br, wherein R is alkyl, aryl, acyl or sulfonyl, or R 2 N-Br describes a cyclic structure [e.g. /V-bromosuccinimide (NBS), ⁇ /, ⁇ /'-dibromoisocyanuric acid (DBI) or N,N'- dibromohydantoin (DBH)]:
  • NSS V-bromosuccinimide
  • DBI ⁇ /, ⁇ /'-dibromoisocyanuric acid
  • DBH N,N'- dibromohydantoin
  • the catalyst contemplated in the method of the invention may be any suitable H + or a Lewis acid.
  • the Lewis acid may in particular be a compound of the formula M' m X n ,, where M' represents a metal, and X represents halogen.
  • Preferred Lewis acids are e.g. BF 3 , AIX 3 , TiX 4 , ZnX 2 , MnX 2 , FeX 3 , FeX 2 , SnX 2 , PbX 2 , SbX 3 , and SbX 5 .
  • the solvent is an acid with or without H 2 O, e.g. FSO 3 H, CISO 3 H, CF 3 SO 3 H, H 2 SO 4 ,
  • the solvent is an acid with or without H2O i.e. HCI (0.1 N to cone), CF3SO3H, H 2 SO 4 , CH3SO3H, CF3COOH or CH3COOH.
  • the solvent functions as a catalyst.
  • MNO3 is a nitrating reagent as known in the art, wherein M represents a metal or H + .
  • the active component being NO 2 + formed in situ in the reaction mixture.
  • the method of the invention may be conducted at temperatures ranging from -50 °C to 200 °C with the temperature range between -30 °C to -15 °C being the preferred for the preparation of the 5- or 8-bromoisoquinolines.
  • the method of the invention may be conducted from 0.1 g to 500 kg scale with the preferred scale being 1 g to 50 kg. Finally, the reaction may be conducted at 0.1 M to 5 M concentration with a preferred concentration of 0.5-1 M.
  • the method of the invention may be quenched after bromination giving 5-bromo or 8- bromoisoquinoline or continued by addition of metal nitrate, whereby 5-bromo-8- nitroisoquinoline or 8-bromo-5-nitroisoquinoline may be isolated from a "ONE POT" reaction.
  • 5-bromoisoquinoline and 5-bromo-8-nitroisoquinoline may in broad terms be described as a transformation of isoquinoline to 5-bromoisoquinoline using strong acid, preferably cone. H2SO4, and a brominating agent, preferably NBS.
  • the bromination is preferably conducted at 0.5-1 M scale at a temperature of -30 °C to -15°C.
  • 5- Bromoisoquinoline may be worked up and isolated as pure material or it may be further transformed, without prior isolation into 5-bromo-8-nitroisoquinoline by addition of potassium nitrate to the reaction mixture. Workup and recrystalization gives pure 5-bromo-8- nitroisoquinoline. Examples
  • NBS NBS > DBH.
  • NBS and DBH are commercially available and DBI is very easy to make from elemental bromine, lithium hydroxide and cyanuric acid according to the procedure of Gottardi.
  • the reaction temperature is very important in order to achieve a high 5- vs. 8-selectivity and should not be above -15 °C during the bromination. 5.
  • the crude product was typically of the following composition: 5-Bromo-8-nitroisoquinolin/5,8-dibromoisoquinoline/5-nitroisoquinoline/8-bromo-5- nitroisoquinoline:
  • the purified product was typically of the following composition: 5-Bromo-8-nitroisoquinolin/5,8-dibromoisoquinoline/5-nitroisoquinoline/8-bromo-5- nitroisoquinoline: >97%/ ⁇ 1 %/ ⁇ 1 %/ ⁇ 1 %.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PCT/DK1999/000347 1998-06-22 1999-06-22 Method of preparing 5- or 8-bromoisoquinoline derivatives Ceased WO1999067218A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT99927733T ATE250584T1 (de) 1998-06-22 1999-06-22 Synthese von 5- oder 8-bromoisoquinolin derivaten
DK99927733T DK1089976T3 (da) 1998-06-22 1999-06-22 Fremgangsmåde til fremstilling af 5-bromisoquinolin og dets 8-nitroderivat
JP2000555872A JP2002518480A (ja) 1998-06-22 1999-06-22 5−又は8−ブロモイソキノリン誘導体の製造方法
EP99927733A EP1089976B1 (en) 1998-06-22 1999-06-22 Method of preparing 5- or 8-bromoisoquinoline derivatives
DE69911603T DE69911603T2 (de) 1998-06-22 1999-06-22 Synthese von 5- oder 8-bromoisoquinolin derivaten
AU44987/99A AU4498799A (en) 1998-06-22 1999-06-22 Method of preparing 5- or 8-bromoisoquinoline derivatives
US09/685,025 US6500954B1 (en) 1998-06-22 2000-10-10 Synthesis of 5- or 8-bromoisoquinoline derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199800884 1998-06-22
DKPA199800884 1998-06-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/685,025 Continuation US6500954B1 (en) 1998-06-22 2000-10-10 Synthesis of 5- or 8-bromoisoquinoline derivatives

Publications (2)

Publication Number Publication Date
WO1999067218A2 true WO1999067218A2 (en) 1999-12-29
WO1999067218A3 WO1999067218A3 (en) 2000-03-16

Family

ID=8098619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000347 Ceased WO1999067218A2 (en) 1998-06-22 1999-06-22 Method of preparing 5- or 8-bromoisoquinoline derivatives

Country Status (8)

Country Link
US (1) US6500954B1 (enExample)
EP (1) EP1089976B1 (enExample)
JP (1) JP2002518480A (enExample)
AT (1) ATE250584T1 (enExample)
AU (1) AU4498799A (enExample)
DE (1) DE69911603T2 (enExample)
DK (1) DK1089976T3 (enExample)
WO (1) WO1999067218A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
BR0312727A (pt) * 2002-07-17 2005-04-19 Warner Lambert Co Combinação de um inibidor alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
ATE374030T1 (de) * 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
WO2005025675A1 (en) * 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
DE102005061997A1 (de) * 2005-12-23 2007-07-05 Basf Ag Naphthalintetracarbonsäurederivate und deren Verwendung
CN113264880B (zh) * 2021-05-25 2022-08-30 湖北工业大学 一种4-卤代异喹啉化合物的制备方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A.R. OSBORN ET AL.: JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY,1956, pages 4191-4204, XP002126750 LETCHWORTH GB cited in the application *
I.W. MATHISON ET AL.: JOURNAL OF ORGANIC CHEMISTRY, vol. 39, no. 22, 1974, pages 3210-3215, XP002126748 EASTON US cited in the application *
J.L BUTLER ET AL.: TRANS. KY. ACAD. SCI., vol. 38, no. 1-2, 1977, pages 15-20, XP000856760 cited in the application *
M. GORDON ET AL.: JOURNAL OF ORGANIC CHEMISTRY, vol. 29, 1964, pages 329-332, XP002126751 EASTON US cited in the application *
M. REY ET AL.: HELVETICA CHIMICA ACTA, vol. 68, no. 7, 1985, pages 1828-1834, XP002126749 BASEL CH cited in the application *

Also Published As

Publication number Publication date
DE69911603D1 (de) 2003-10-30
JP2002518480A (ja) 2002-06-25
WO1999067218A3 (en) 2000-03-16
US6500954B1 (en) 2002-12-31
DE69911603T2 (de) 2004-07-29
EP1089976B1 (en) 2003-09-24
AU4498799A (en) 2000-01-10
DK1089976T3 (da) 2004-01-19
ATE250584T1 (de) 2003-10-15
EP1089976A1 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
US20030100779A1 (en) Process for preparing pentacene derivatives
US4541954A (en) Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP1089976B1 (en) Method of preparing 5- or 8-bromoisoquinoline derivatives
US5034541A (en) Method of preparing 1-phenyl-1-diethylaminocarbonyl-2-phthalimidomethyl-cyclopropane-z
US3966813A (en) Process for the preparation of 1-(m- and p-hydroxyphenyl)-2-aminoethanol
JP2002518480A5 (enExample)
Wright Jr et al. Central nervous system depressants. IV. 2-Aminoalkyl-1, 2-dihyro-3H-imidazo [1, 5-a] indol-3-ones
US2989539A (en) J-amino-x-phenylpyrazoles and method
DICE et al. AMINOPHENANTHRENE DERIVATIVES PREPARED BY THE SCHMIDT REACTION1
El-Emam et al. Adamantane derivatives IV: Unexpected debenzylation on ring closure of 1-(1-adamantylcarbonyl)-4-benzylthiosemicarbazide with sulphuric acid
Mulhern et al. A practical ortholithiation-based synthesis of 2-chloro-6-methylaniline
DE1545942A1 (de) Verfahren zur Herstellung von Chinazolin-Derivaten
US4211877A (en) Method of preparation of isopropyl 4,10-dihydro-10-oxothieno[3,2-c][1]benzoxepin-8-acetate
US4570001A (en) Process for synthesizing certain N-benzoylamino indolines
EP0347136B1 (en) Method for reducing aromatic nitro groups
EP1207153A1 (en) Process for the preparation of indole derivatives or salts thereof
JP2001278867A (ja) 環式酸の製造
US4684732A (en) Process for preparation of phthalide derivatives
US3671589A (en) Process for preparation of 2-substituted-1,3-cyclopentanediones
US3134786A (en) 5,11-diloweralkylindolo[3,2-b]carbazole-6,12(5h,11h)-dione
US3280129A (en) Process for d-lysergic acid halide hydrohalides
EP3640235B1 (en) Process for the preparation of cyclic peri-succinoylacenaphthene and related 1,4-diketo compounds
JPH05331139A (ja) 2−アザビシクロ[2.2.1ヘプト−5−エン−3−オンの製造法
JPS62230784A (ja) ジヒドロ−1h−ピロリジン−3,5−(2h,6h)−ジオンの製法
JPH05331140A (ja) 2−アザビシクロ[2.2.1ヘプト−5−エン−3−オンの製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999927733

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09685025

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999927733

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1999927733

Country of ref document: EP